Novartis Investigative Site

Bowling Green, Kentucky 42101

0 studies enrolling now · 9 studies all time

What they study most

Ankylosing Spondylitis, Chronic Obstructive Pulmonary Disease (COPD), Non-radiographic Spondyloarthritis, Psoriatic Arthritis, Rheumatoid Arthritis

Studies at this site

• Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis — Completed
• Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA — Completed
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis — Completed
• 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) — Completed
• A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation — Completed
• Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate — Completed